Gujarat Themis Biosyn: Promoters Confirm No Share Encumbrance in FY26
Gujarat Themis Biosyn Limited promoters confirmed no share encumbrance in FY26. Previous disclosures for FY23-24 and FY25-26 concerning pledged shares by Pharmaceutical Business Group (India) Ltd and Themis Medicare Ltd have been made. This is a regulatory disclosure under SEBI Takeover Regulations.
This is a standard disclosure under SEBI regulations confirming the status of share encumbrances. It does not introduce new information that would significantly affect the company's stock price or business operations.
The announcement is a routine regulatory disclosure confirming no new encumbrances on shares. It does not contain any new financial information or significant business updates that would positively or negatively impact the company's outlook.
Gujarat Themis Biosyn Limited announced that its promoters and promoter group, including Dr. Dinesh S. Patel, Jayshree Dinesh Patel, Sachin Dinesh Patel, Reena Sachin Patel, Anay Rupen Choksi, Nysha Rupen Choksi, Pharmaceutical Business Group (India) Limited, and Themis Medicare Limited, have confirmed that no encumbrance has been made over their shares during the financial year ended March 31, 2026.
The company clarified that disclosures regarding shares pledged by Pharmaceutical Business Group (India) Limited in FY23-24 were previously made. Furthermore, disclosures concerning pledged shares held by Themis Medicare Limited in FY25-26 have also been duly intimated to the BSE Limited and the National Stock Exchange of India Limited as per applicable regulations.
This disclosure is made in accordance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.